Current Rheumatology Reports

, Volume 6, Issue 4, pp 306–313

Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis

  • Wendy Myers
  • Mobolaji Opeola
  • Alice B. Gottlieb


Psoriasis and psoriatic arthritis are chronic inflammatory diseases that significantly affect patients’ quality of life. Not only do these diseases impact patients’ physical well-being, but also detrimentally affect their life socially and psychologically. There are many different patterns of skin and joint involvement. Understanding the pathogenesis of these diseases has evolved greatly in the past few decades. It is now understood that psoriasis and psoriatic arthritis are T cell mediated disorders. A number of proinflammatory cytokines have been suggested as playing a role in the disease mechanism, such as tumor necrosis factor-α and interferon-γ. Other important factors proposed in the pathogenesis of these diseases include the role of genetics and environmental factors. New immunomodulating therapies, which are being developed as our understanding of the involvement of innate and adaptive immunity advances, will provide patients with safer, more effective, long-term, management options.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lebwohl M: Psoriasis. Lancet 2003, 361:1197–1204.PubMedCrossRefGoogle Scholar
  2. 2.
    Buntin DM, Skinner RB Jr., Rosenberg EW: Onset of psoriasis at age 108. J Am Acad Dermatol 1983, 9:276–277.PubMedCrossRefGoogle Scholar
  3. 3.
    Ferrandiz C, Pujol RM, Garcia-Patos V, et al.: Psoriasis of early and late onset: A clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002, 46:867–873.PubMedCrossRefGoogle Scholar
  4. 4.
    Roenigk HH: Skin manifestations of psoriasis. In Psoriasis. Edited by Roenigk HH, Maibach HI. New York: Marcel Dekker, Inc; 1991:3–9.Google Scholar
  5. 5.
    Galadari H, Fuchs B, Lebwohl M: Newly available treatments for psoriatic arthritis and their impact on skin psoriasis. Int J Dermatol 2003, 42:231–237.PubMedCrossRefGoogle Scholar
  6. 6.
    Winchester R: Psoriatic arthritis. In Dermatology in General Medicine. Edited by Fitzpatrick T, Gisen A, Wolff K, Freedberg I, Austen K. New York: McGraw-Hill, Inc.; 1993:515–527.Google Scholar
  7. 7.
    Brockbank J, Gladman D: Diagnosis and management of psoriatic arthritis. Drugs 2002, 62:2447–2457.PubMedCrossRefGoogle Scholar
  8. 8.
    Gupta MA, Gupta AK: Quality of life of psoriasis patients. J Eur Acad Dermatol Venereol 2000, 14:241–242.PubMedCrossRefGoogle Scholar
  9. 9.
    Christophers E, Sterry W: Epidermis: disorders of cell kinetics and differentiation. In Dermatology in General Medicine. Edited by Fitzpatrick T, Gisen A, Wolff K, Freedberg I, Austen K. New York: McGraw-Hill, Inc.; 1993:489–512.Google Scholar
  10. 10.
    Arnold H, Odom B, James W: Andrew’s Diseases of Skin: Clinical Dermatology. Philadelphia: W.B. Saunders Company; 1990.Google Scholar
  11. 11.
    Farber EM, Nall L: Pustular psoriasis. Cutis 1993, 51:29–32.PubMedGoogle Scholar
  12. 12.
    National Psoriasis Foundation. Accessed September 19, 2003.Google Scholar
  13. 13.
    van de Kerkhof PC, Franssen ME: Psoriasis of the scalp: diagnosis and management. Am J Clin Dermatol 2001, 2:159–165.PubMedCrossRefGoogle Scholar
  14. 14.
    Cockayne SE, Messenger AG: Familial scarring alopecia associated with scalp psoriasis. Br J Dermatol 2001, 144:425–427.PubMedCrossRefGoogle Scholar
  15. 15.
    Chalmers RJ, O’Sullivan T, Owen CM, Griffiths CE: A systematic review of treatments for guttate psoriasis. Br J Dermatol 2001, 145:891–894.PubMedCrossRefGoogle Scholar
  16. 16.
    Fitzpatrick TB, Johnson RA, Wollf K, et al.: Color Atlas and Synopsis of Clinical Dermatology-Common and Serious Diseases. New York: McGraw-Hill; 1997.Google Scholar
  17. 17.
    Drew GS: Dermatology-psoriasis. Prim Care 2000, 27:385–406.PubMedGoogle Scholar
  18. 18.
    Weinstein GD, Gottlieb AB: Therapy of Moderate-to-Severe Psoriasis. New York: Marcel Dekker, Inc.; 2003. Up-to-date reviews of available traditional and biologic therapies.Google Scholar
  19. 19.
    Peters BP, Weissman FG, Maka G: Pathophysiology and treatment of psoriasis. Am J Health Syst Pharm 2000, 57:645–662.PubMedGoogle Scholar
  20. 20.
    Green MS, Prystowsky JH, Cohen SR: Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996, 34:911–914.PubMedCrossRefGoogle Scholar
  21. 21.
    Kumar B, Saraswat A, Kaur I: Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol 2002, 82:192–195.PubMedCrossRefGoogle Scholar
  22. 22.
    Gottlieb AB, Chaudhari U, Baker DG, et al.: The national psoriasis score (NPF-PS) system versus the psoriasis area severity index and physician’s global assessment (PGA): a comparison. J Drugs Dermatol 2003, 3:260–266.Google Scholar
  23. 23.
    Krueger JG, Feldman SR, Camisa C, et al.: Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis. J Am Acad Dermatol 2000, 43:281–285. This article outlines the importance of quality of life in assessment psoriasis severityPubMedCrossRefGoogle Scholar
  24. 24.
    Michet CJ: Psoriatic arthritis. In Textbook of Rheumatology. Edited by Kelley WN, Harris ED, Ruddy S, Sledge CB. Philadelphia: W.B. Saunders Company; 1993:974–984.Google Scholar
  25. 25.
    Gottlieb AB: Psoriasis-immunopathology and immunomodulation. Dermatol Clin 2001, 19:649–657.PubMedCrossRefGoogle Scholar
  26. 26.
    Granstein RD: New treatments for psoriasis. N Engl J Med 2001, 345:284–287.PubMedCrossRefGoogle Scholar
  27. 27.
    Mehlis SL, Gordon KB: The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003, 49(Suppl 2):S44-S50.PubMedCrossRefGoogle Scholar
  28. 28.
    Nickoloff BJ: The immunologic and genetic basis of psoriasis. Arch Dermatol 1999, 135:1104–1110.PubMedCrossRefGoogle Scholar
  29. 29.
    Kreuger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002, 46:1–23.CrossRefGoogle Scholar
  30. 30.
    Fearon U, Veale DJ: Pathogenesis of psoriatic arthritis. Clin Exp Dermatol 2001, 26:333–337.PubMedCrossRefGoogle Scholar
  31. 31.
    Ritchlin CT, Haas-Smith SA, Li P, et al.: Mechanisms of TNF-a and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821–831.PubMedCrossRefGoogle Scholar
  32. 32.
    Gottlieb AB, Bos JD: Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002, 105:105–116.PubMedCrossRefGoogle Scholar
  33. 33.
    Gottlieb AB, Krueger JG, Wittkowski K, et al.: Psoriasis as a model for T-cell mediated disease-immunobiologic and clinical effects of treatment with multiple doses of Efalizamab, an anti-CD11a antibody. Arch Dermatol 2002, 138:591–600.PubMedCrossRefGoogle Scholar
  34. 34.
    Singri P, West DP, Gordon KB: Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002, 138:657–663.PubMedCrossRefGoogle Scholar
  35. 35.
    Gottlieb AB, Masad S, Ramamurthi R, et al.: Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatments of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003, 48:68–75.PubMedCrossRefGoogle Scholar
  36. 36.
    Mehrabi D, Dicarlo JB, Soon SL, McCall CO: Advances in the management of psoriasis: monoclonal antibody therapies. Int J Dermatol 2002, 41:827–835.PubMedCrossRefGoogle Scholar
  37. 37.
    Chaudhari U, Romano P, Mulcahy LD, et al.: Infliximab monotherapy in the treatment of plaque-type psoriasis. Lancet 2001, 357:1842–1847. First, double blind, placebo controlled trial of infliximab monotherapy for psoriasis.PubMedCrossRefGoogle Scholar
  38. 38.
    Leonardi C, Powers JL, Matheson RT, et al.: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003, 349:2014–2022.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2004

Authors and Affiliations

  • Wendy Myers
  • Mobolaji Opeola
  • Alice B. Gottlieb
    • 1
  1. 1.Clinical Research Center, UMDNJ- Robert Wood Johnson Medical, SchoolNew BrunswickUSA

Personalised recommendations